These two large-cap drug giants should be core parts of any well-diversified portfolio.
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
The indices may test intraday lows, which we haven't seen at this point in the day in a very long time.

Amgen Shows a Bullish Breakout Real Money Pro($)

There is more upside to come for this stock.
A trade at $126 will be a new high for the move up.

Biotech Buoyed by Deal Talk Real Money Pro($)

M&A activity is in a serious upswing, and here are some names to watch.

Bullish Momentum for Regeneron Real Money Pro($)

Volatility has calmed down, and there are bullish signs.
You need to see where the health services giant normally trades to appreciate how undervalued it is.
Don't fight the trend of this stock.
They can close out early if the trade isn't going their way.

Columnist Conversations

Vacation company Norwegian Cruise Line Holdings (NCLH) posted improved results in its latest quarter.  ...
Nice move in GPS today. The stock is up 2.7% late in the session and is holding above last month's peak($24.93...
I have read her book, 'Dare to Serve' and have seen her interviewed multiple times by Jim Cramer on Mad Money....


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.